Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, T-Cell
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, T-Cell
Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Lymphoma » Lymphoma, Non-Hodgkin » Lymphoma, T-Cell
Description
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes. MeSH
Hierarchy View
Subtype Terms (5)
Enteropathy-Associated T-Cell Lymphoma
25 drugs (18 approved, 7 experimental)
Lymphoma, Extranodal NK-T-Cell
56 drugs (35 approved, 21 experimental)
Lymphoma, Large-Cell, Anaplastic
146 drugs (89 approved, 57 experimental)
Lymphoma, T-Cell, Cutaneous
80 drugs (46 approved, 34 experimental)
Lymphoma, T-Cell, Peripheral
153 drugs (85 approved, 68 experimental)
Approved Indicated Drugs (6)
Phase 4 Indicated Drugs (23)
Phase 3 Indicated Drugs (18)
Phase 2 Indicated Drugs (79)
allogeneic hematopoietic stem cells (Hemacord)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous cd19/cd22 chimeric antigen receptor t-cells
autologous hematopoietic stem cells
autologous mononuclear stem cell
autologous umbilical cord blood
Other Experimental Indicated Drugs (10)
Organization Involved with Phase 4 Indications (28)
Organization Involved with Phase 3 Indications (31)
Organization Involved with Phase 2 Indications (229)
Arbeitsgemeinschaft medikamentoese Tumortherapie
Badalona Hospital Germans Trias i Pujol
Big Ten Cancer Research Consortium
Boca Raton Clinical Research Associates
Bronx River Medical Associates, PC
Cancer and Leukemia Group B (CALGB)
City of Hope National Medical Center
Consortium for Improving Survival of Lymphoma
Cyclacel Pharmaceuticals, Inc.
Department of Lymphoma and Hematology, Hunan Cancer Hospital
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Drs Pirjol, Szpak and Moodley Inc, Durban, South Africa
Eastern Cooperative Oncology Group
Florida Academic Dermatology Centers
Hospital Universitario Central de Asturias
Innovative Therapies For Children with Cancer Consortium
Innovent Biologics (Suzhou) Co. Ltd.
International Extranodal Lymphoma Study Group
Isala Clinics, Zwolle, The Netherlands
James Graham Brown Cancer Center
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Jiangxi Provincial Cancer Hospital
Johannes Wesling Klinikum, Minden, Germany
Josep Carreras Leukaemia Research Institute
Karl Landsteiner Private University of Health Sciences
Koordinierungszentren für Klinische Studien bzw. Zentren für klinische Studien
Memorial Sloan-Kettering Cancer Center
Nanjing NingQi Medicine Science and Technology Co., Ltd.
National Institutes of Health (NIH)
Norwegian University of Science and Technology
Ospedale Maggiore Azienda Sanitaria Universitaria Trieste Ematologia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Philipps University of Marburg
Rochester Skin Lymphoma Medical Group, PLLC
Royal Marsden Hospital NHS Trust
Shandong New Time Pharmaceutical Co., LTD
Shijiazhuang Pharma Group (CSPC)
Simcere Pharmaceutical Co., Ltd
State University of New York, Buffalo
State University of New York, Syracuse
The Christie NHS Foundation Trust
The First People's Hospital of Lianyungang
The Lymphoma Study Association
The University of Texas, Dallas
Universidad Complutense de Madrid
Universitario de Santiago, Spain
Université catholique de Louvain
University of Alabama, Birmingham
University of California, Los Angeles
University of California, San Francisco
University of Colorado, Denver
University of Medicine and Dentistry of New Jersey
University of Modena and Reggio Emilia
University of North Carolina at Chapel Hill
Virginia Commonwealth University
Organization Involved with Phase 1 Indications (38)
Organization Involved with Other Experimental Indications (4)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
